Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy

被引：0
|
作者：
O'Kane, Grainne M.
Denroche, Rob
Picardo, Sarah Louise
Zhang, Amy
Holter, Spring
Grant, Robert C.
Allen, Michael
Wang, Yifan
Dodd, Anna
Ramotar, Stephanie
Hutchinson, Shawn
Tehfe, Mustapha
Biagi, James Joseph
Wilson, Julie
Notta, Faiyaz
Fischer, Sandra
Zogopoulos, George
Gallinger, Steven
Knox, Jennifer J.
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Ontario Inst Canc Res, Toronto, ON, Canada
[3] Beaumont Hosp, Dept Med Oncol, Dublin, Ireland
[4] Ontario Inst Canc Res, Toronto, ON, Canada
[5] Samuel Lunenfeld Res Inst, Toronto, ON, Canada
[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[7] McGill Univ, Montreal, PQ, Canada
[8] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] CHU Montreal, Hop Notre Dame, Montreal, PQ, Canada
[10] Queens Univ, Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[11] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada
[12] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[13] Toronto Gen Hosp, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
741
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Analysis of homologous recombination deficiency (HRD) scores in osteosarcoma
    Kinnaman, Michael David
    Pena, Julia
    Levine, Max
    Bouvier, Nancy
    Papaemmanuil, Elli
    Forrest, Suzanne
    Janeway, Katherine
    Meyers, Paul
    Bender, Julia Glade
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Impact of advances in systemic chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC) in Alberta, Canada
    Lee-Ying, R.
    Loree, J.
    Cheung, W. Y.
    Tang, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] MULTISITE INTRATUMORAL CHEMOTHERAPY RETARDS GROWTH OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IN A MURINE MODEL
    Lazarovits, Janette
    Epelbaum, Ron
    Lachter, Jesse
    Amikam, Yaron
    Benarie, Jacob
    GASTROINTESTINAL ENDOSCOPY, 2023, 97 (06) : AB724 - AB725
  • [24] Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
    Javed, Muhammad Ahsan
    Beyer, Georg
    Le, Nha
    Vinci, Alessio
    Wong, Helen
    Palmer, Daniel
    Morgan, Robert D.
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    Alam, Salma
    Chowdhury, Sumsur
    Ma, Yuk Ting
    Archibugi, Livia
    Capurso, Gabriele
    Maisonneuve, Patrick
    Neesse, Albrecht
    Sund, Malin
    Schober, Marvin
    Krug, Sebastian
    PANCREATOLOGY, 2019, 19 (01) : 97 - 104
  • [25] Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer
    Richardson, Andrea L.
    Silver, Daniel P.
    Szallasi, Zoltan
    Birkbak, Nicolai J.
    Wang, Zhigang C.
    Iglehart, J. Dirk
    Mayer, Erica L.
    Winer, Eric P.
    Tung, Nadine M.
    Ryan, Paula D.
    Isakoff, Steven J.
    Barry, William T.
    Greene-Collozi, April
    Gutin, Alexander
    Reid, Julia
    Neff, Chris
    Jones, Joshua
    Timms, Kirsten
    Hartman, Anne-Renee
    Garber, Judy E.
    CANCER RESEARCH, 2015, 75
  • [26] Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)
    Markus, M.
    Kasper, S.
    Noureddine, R.
    Abramczyk, M.
    Paul, A.
    Gerken, G.
    Schmid, K. W.
    Markus, P.
    Schumacher, B.
    Meiler, J.
    Wiesweg, M.
    Kaiser, G.
    Dechene, A.
    Trarbach, T.
    Schuler, M.
    Abendroth, A.
    Oncology Research and Treatment, 2015, 38 : 4 - 5
  • [27] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    LABORATORY INVESTIGATION, 2018, 98 : 680 - 680
  • [28] The Beginning of the End of Nihilism in Pancreatic Ductal Adenocarcinoma (PDAC)?
    Johnson, K. M.
    Firpo, M. A.
    Boucher, K. M.
    Scaife, C. L.
    Mulvihill, S. J.
    PANCREAS, 2013, 42 (08) : 1357 - 1357
  • [29] Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
    Babiker, Hani M.
    Karass, Michael
    Recio-Boiles, Alejandro
    Chandana, Sreenivasa R.
    McBride, Ali
    Mahadevan, Daruka
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (07) : 583 - 592
  • [30] Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).
    Mehdi, Maahum
    Kamgar, Mandana
    George, Ben
    Szabo, Aniko
    Annunzio, Kaitlin
    Taylor, Bradley W.
    Shreenivas, Aditya Varnam
    Chakrabarti, Sakti
    Thomas, James P.
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Clarke, Callisia
    Hall, William Adrian
    Erickson, Beth
    Ahmed, Gulrayz
    Thapa, Bicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345